1. Olefir YuV. Rezul'taty provedennogo analiza i obobshcheniya materialov po bezopasnosti klinicheskikh issledovanii. Bezopasnost' i risk farmakoterapii. 2017;(1):5–10. [Olefir YuV. The results of the analysis of materials on the safety of clinical trials. Bezopasnost i risk farmakoterapii=Safety and Risk of Pharmacotherapy. 2017;(1):5–10 (In Russ.)]
2. Goryachev DV, Tel'nykh MYu, Bunyatyan ND. Regulyatornye podkhody k otsenke bioanalogov dlya lecheniya revmaticheskikh zabolevanii. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. 2017;(3):155–63. [Goryachev DV, Telnykh MYu, Bunyatyan ND. Regulatory approaches to evaluation of biosimilars for treatment of rheumatic diseases. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya=The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;(3):155–63 (In Russ.)]
3. Zakharov VV. Kognitivnye narusheniya v nevrologicheskoi praktike. Trudnyi patsient. 2005;3(5):4–9. [Zakharov VV. Cognitive disorders in neurological practice. Trudny patsient=Difficult Patient. 2005;3(5):4–9 (In Russ.)]
4. Damulin IV. Sosudistaya dementsiya: nekotorye patogeneticheskie, diagnosticheskie i terapevticheskie aspekty. Russkii meditsinskii zhurnal. 2008;16(5):253–8. [Damulin IV. Vascular dementia: some pathogenetic, diagnostic and therapeutic aspects. Russkiy meditsinskiy zhurnal=Russian Medical Journal. 2008;16(5):253–8 (In Russ.)]
5. Larrabee GJ, Crook TH. Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function. Int Psychogeriatr. 1994;6(1):95–104.